US5961970A
(en)
|
1993-10-29 |
1999-10-05 |
Pharmos Corporation |
Submicron emulsions as vaccine adjuvants
|
US5744137A
(en)
*
|
1995-02-06 |
1998-04-28 |
The United States Of America As Represented By The Secretary Of The Agriculture |
Oil emulsion vaccines prepared with animal, vegetable, and synthetic oils using a mixture of nonionic surfactants
|
US6488933B2
(en)
|
1995-07-05 |
2002-12-03 |
Yeda Research And Development Co. Ltd. |
Preparations for the treatment of T cell mediated diseases
|
CN1211192A
(en)
*
|
1995-09-18 |
1999-03-17 |
美国陆军医疗材料研究指挥部 |
Improved methods for the production of non-covalently complexed and multivalent proteosome sub-unit vaccines
|
WO1997029773A1
(en)
*
|
1996-02-13 |
1997-08-21 |
The Nisshin Oil Mills, Ltd. |
Vaccine-containing emulsion and vaccine-containing powder for oral administration and process for producing the same
|
EP0929678A2
(en)
*
|
1996-07-10 |
1999-07-21 |
ID Biomedical Corporation of Maryland |
Protein and peptide vaccines for inducing mucosal immunity
|
GB9711990D0
(en)
*
|
1997-06-11 |
1997-08-06 |
Smithkline Beecham Biolog |
Vaccine
|
GB9717905D0
(en)
|
1997-08-22 |
1997-10-29 |
Univ Aston |
Lipid-containing compositions and uses thereof
|
CA2306090A1
(en)
*
|
1997-10-24 |
1999-05-06 |
Christopher W. Mcdaniel |
Delivery vehicles for bioactive agents and uses thereof
|
US6534070B1
(en)
|
1997-11-19 |
2003-03-18 |
Schering Aktiengesellschaft |
Composition with azelaic acid
|
IN187039B
(en)
|
1997-12-08 |
2001-12-29 |
Council Scient Ind Res |
|
FR2776928B1
(en)
*
|
1998-04-03 |
2000-06-23 |
Merial Sas |
ADJUVATED DNA VACCINES
|
AU4376199A
(en)
*
|
1998-06-26 |
2000-01-17 |
Pasteur Merieux Serums Et Vaccins |
Mucosal targeting immunisation
|
EP0997734B1
(en)
*
|
1998-10-29 |
2006-09-27 |
Council of Scientific and Industrial Research |
Composition useful for the early diagnosis of visceral leishmaniasis and a process for preparing the same
|
AU769539B2
(en)
*
|
1999-01-29 |
2004-01-29 |
Zoetis Services Llc |
Adjuvants for use in vaccines
|
US7915238B2
(en)
|
1999-02-01 |
2011-03-29 |
Eisai R & D Management Co., Ltd. |
Immunomodulatory compounds and methods of use thereof
|
US20040006242A1
(en)
|
1999-02-01 |
2004-01-08 |
Hawkins Lynn D. |
Immunomodulatory compounds and method of use thereof
|
US6835721B2
(en)
|
1999-02-01 |
2004-12-28 |
Eisai Co., Ltd. |
Immunomodulatory compounds and methods of use thereof
|
KR100711561B1
(en)
*
|
1999-02-01 |
2007-04-27 |
에-자이가부시기가이샤 |
Immunological adjuvant compound
|
JP2002537355A
(en)
*
|
1999-02-26 |
2002-11-05 |
カイロン コーポレイション |
Use of bioadhesives and adjuvants for mucosal delivery of antigen
|
US6475800B1
(en)
*
|
1999-07-22 |
2002-11-05 |
Instrumentation Metrics, Inc. |
Intra-serum and intra-gel for modeling human skin tissue
|
ATE331530T1
(en)
|
2000-02-15 |
2006-07-15 |
Id Biomedical Corp Quebec |
PROTEASOME INFLUENZA VIRUS VACCINE COMPOSITION G
|
FR2809961B1
(en)
*
|
2000-06-09 |
2004-12-03 |
Seppic Sa |
USE OF SUGAR ETHERS AS IMMUNITY ADDITIVES IN VACCINE COMPOSITIONS, THERAPEUTIC COMPOSITIONS CONTAINING THEM AND THEIR USE AS VACCINES
|
DE60115051T2
(en)
|
2000-07-31 |
2006-08-24 |
Eisai Co., Ltd. |
IMMUNOLOGICAL ADJUVANS COMPOUNDS
|
MY134424A
(en)
*
|
2001-05-30 |
2007-12-31 |
Saechsisches Serumwerk |
Stable influenza virus preparations with low or no amount of thiomersal
|
WO2004030608A2
(en)
*
|
2001-06-05 |
2004-04-15 |
The Regents Of The University Of Michigan |
Nanoemulsion vaccines
|
IL145926A0
(en)
|
2001-10-15 |
2002-07-25 |
Mor Research Applic Ltd |
Peptide epitopes of mimotopes useful in immunomodulation
|
CN1767854B
(en)
*
|
2003-04-04 |
2013-07-24 |
硕腾P有限责任公司 |
Microfluidized oil-in-water emulsions and vaccine compositions
|
NZ561823A
(en)
|
2005-03-23 |
2010-04-30 |
Glaxosmithkline Biolog Sa |
Use of an influenza virus and an oil-in-water emulsion adjuvant to induce cd4 t-cell and/or improved b-memory cell response
|
EP1874342B1
(en)
|
2005-04-26 |
2018-06-06 |
Eisai R&D Management Co., Ltd. |
Compositions and methods for cancer immunotherapy
|
GB2426703B
(en)
|
2005-05-31 |
2007-09-19 |
Malvern Cosmeceutics Ltd |
Compositions
|
CN103012169B
(en)
*
|
2005-06-30 |
2016-04-20 |
卫材R&D管理有限公司 |
For the preparation of the compound of immunological adjuvant
|
JP2009514839A
(en)
|
2005-11-04 |
2009-04-09 |
ノバルティス ヴァクシンズ アンド ダイアグノスティクス エスアールエル |
Adjuvant influenza vaccine containing cytokine inducer
|
DK2368572T3
(en)
|
2005-11-04 |
2020-05-25 |
Seqirus Uk Ltd |
Adjuvant vaccines with non-virion antigens produced from influenza viruses grown in cell culture
|
US20090304742A1
(en)
|
2005-11-04 |
2009-12-10 |
Novartis Vaccines And Diagnostics Srl |
Influenza vaccines with reduced amount of emulsion adjuvant
|
WO2007052061A2
(en)
|
2005-11-04 |
2007-05-10 |
Novartis Vaccines And Diagnostics Srl |
Emulsions with free aqueous-phase surfactant as adjuvants for split influenza vaccines
|
WO2007085969A2
(en)
|
2006-01-27 |
2007-08-02 |
Novartis Vaccines And Diagnostics Gmbh & Co Kg |
Influenza vaccines containing hemagglutinin and matrix proteins
|
JP2009534303A
(en)
|
2006-03-24 |
2009-09-24 |
ノバルティス ヴァクシンズ アンド ダイアグノスティクス ゲーエムベーハー アンド カンパニー カーゲー |
Preserving influenza vaccines that are not refrigerated
|
EP2019686B1
(en)
|
2006-03-31 |
2012-07-11 |
Novartis AG |
Combined mucosal and parenteral immunization against hiv
|
US9839685B2
(en)
|
2006-04-13 |
2017-12-12 |
The Regents Of The University Of Michigan |
Methods of inducing human immunodeficiency virus-specific immune responses in a host comprising nasally administering compositions comprising a naonemulsion and recombinant GP120 immunogen
|
US10138279B2
(en)
|
2006-04-13 |
2018-11-27 |
Regents Of The University Of Michigan |
Compositions and methods for Bacillus anthracis vaccination
|
PL2054431T3
(en)
|
2006-06-09 |
2012-07-31 |
Novartis Ag |
Conformers of bacterial adhesins
|
EP2043682B1
(en)
|
2006-07-17 |
2014-04-02 |
GlaxoSmithKline Biologicals S.A. |
Influenza vaccine
|
GB0614460D0
(en)
|
2006-07-20 |
2006-08-30 |
Novartis Ag |
Vaccines
|
CA3016948A1
(en)
|
2006-09-11 |
2008-03-20 |
Seqirus UK Limited |
Making influenza virus vaccines without using eggs
|
NZ577405A
(en)
|
2006-12-06 |
2012-08-31 |
Novartis Ag |
Vaccines including antigen from four strains of influenza virus
|
GB0700562D0
(en)
|
2007-01-11 |
2007-02-21 |
Novartis Vaccines & Diagnostic |
Modified Saccharides
|
TW200908994A
(en)
|
2007-04-20 |
2009-03-01 |
Glaxosmithkline Biolog Sa |
Vaccine
|
CA2692200A1
(en)
|
2007-06-27 |
2008-12-31 |
Novartis Ag |
Low-additive influenza vaccines
|
GB0714963D0
(en)
|
2007-08-01 |
2007-09-12 |
Novartis Ag |
Compositions comprising antigens
|
EP2462949A3
(en)
|
2007-10-19 |
2012-09-05 |
Novartis AG |
Meningococcal vaccine formulations
|
GB0810305D0
(en)
|
2008-06-05 |
2008-07-09 |
Novartis Ag |
Influenza vaccination
|
GB0818453D0
(en)
|
2008-10-08 |
2008-11-12 |
Novartis Ag |
Fermentation processes for cultivating streptococci and purification processes for obtaining cps therefrom
|
EP2889042A3
(en)
|
2008-03-18 |
2015-10-14 |
Novartis AG |
Improvements in preparation of influenza virus vaccine antigens
|
US9415006B2
(en)
|
2008-05-23 |
2016-08-16 |
The Regents Of The University Of Michigan |
Immunogenic compositions comprising nanoemulsion and hepatitis B virus immunogen and methods of using the same
|
EP2331127A2
(en)
|
2008-09-18 |
2011-06-15 |
Novartis AG |
Vaccine adjuvant combinations
|
AU2009296458A1
(en)
|
2008-09-26 |
2010-04-01 |
Nanobio Corporation |
Nanoemulsion therapeutic compositions and methods of using the same
|
US20120093860A1
(en)
|
2009-02-10 |
2012-04-19 |
Novartis Ag |
Influenza vaccines with increased amounts of h3 antigen
|
PL2396032T3
(en)
|
2009-02-10 |
2017-05-31 |
Seqirus UK Limited |
Influenza vaccines with reduced amounts of squalene
|
EP2942062A1
(en)
|
2009-02-10 |
2015-11-11 |
Novartis AG |
Influenza vaccine regimens for pandemic-associated strains
|
CN102438650A
(en)
|
2009-03-06 |
2012-05-02 |
诺华有限公司 |
Chlamydia antigens
|
JP5668049B2
(en)
|
2009-03-24 |
2015-02-12 |
ノバルティス アーゲー |
Combination of meningococcal factor H binding protein and pneumococcal saccharide conjugate
|
BRPI1013780B8
(en)
|
2009-04-14 |
2022-10-04 |
Novartis Ag |
IMMUNOGENIC COMPOSITION USEFUL FOR IMMUNIZATION AGAINST STAPHYLOCOCCUS AUREUS, ITS PREPARATION METHOD AND PHARMACEUTICAL COMPOSITION
|
EP2401384B1
(en)
|
2009-05-21 |
2012-10-03 |
Novartis AG |
Reverse genetics using non-endogenous pol i promoters
|
JP5823379B2
(en)
|
2009-05-29 |
2015-11-25 |
ノバルティス アーゲー |
Assay for influenza virus hemagglutinin
|
WO2011004263A2
(en)
|
2009-07-07 |
2011-01-13 |
Novartis Ag |
Conserved escherichia coli immunogens
|
EP3988115A3
(en)
|
2009-07-15 |
2022-08-17 |
GlaxoSmithKline Biologicals S.A. |
Rsv f protein compositions and methods for making same
|
AU2010272243A1
(en)
|
2009-07-16 |
2012-03-08 |
Novartis Ag |
Detoxified Escherichia coli immunogens
|
AU2010277310B2
(en)
|
2009-07-31 |
2015-01-15 |
Seqirus UK Limited |
Reverse genetics systems
|
SG178904A1
(en)
|
2009-09-10 |
2012-04-27 |
Novartis Ag |
Combination vaccines against respiratory tract diseases
|
GB0917003D0
(en)
|
2009-09-28 |
2009-11-11 |
Novartis Vaccines Inst For Global Health Srl |
Purification of bacterial vesicles
|
GB0917002D0
(en)
|
2009-09-28 |
2009-11-11 |
Novartis Vaccines Inst For Global Health Srl |
Improved shigella blebs
|
CN102724988B
(en)
|
2009-09-30 |
2014-09-10 |
诺华股份有限公司 |
Expression of meningococcal fHBP polypeptides
|
GB0918392D0
(en)
|
2009-10-20 |
2009-12-02 |
Novartis Ag |
Diagnostic and therapeutic methods
|
PL2491117T3
(en)
|
2009-10-20 |
2014-05-30 |
Novartis Ag |
Improved reverse genetics methods for virus rescue
|
GB0919690D0
(en)
|
2009-11-10 |
2009-12-23 |
Guy S And St Thomas S Nhs Foun |
compositions for immunising against staphylococcus aureus
|
EP2519265B1
(en)
|
2009-12-30 |
2018-11-14 |
GlaxoSmithKline Biologicals SA |
Polysaccharide immunogens conjugated to e. coli carrier proteins
|
GB201003333D0
(en)
|
2010-02-26 |
2010-04-14 |
Novartis Ag |
Immunogenic proteins and compositions
|
US20130071422A1
(en)
|
2010-03-18 |
2013-03-21 |
Michele Pallaoro |
Adjuvanted vaccines for serogroup b meningococcus
|
US20110229516A1
(en)
*
|
2010-03-18 |
2011-09-22 |
The Clorox Company |
Adjuvant phase inversion concentrated nanoemulsion compositions
|
ES2543795T3
(en)
|
2010-03-31 |
2015-08-21 |
Stabilitech Ltd. |
Stabilization of viral particles
|
GB2490644A
(en)
|
2010-03-31 |
2012-11-07 |
Stabilitech Ltd |
Excipients for stabilising viral particles, polypeptides or biological material
|
KR101819250B1
(en)
*
|
2010-03-31 |
2018-01-16 |
스타빌리테크 리미티드 |
Method for preserving alum adjuvants and alum-adjuvanted vaccines
|
GB201005625D0
(en)
|
2010-04-01 |
2010-05-19 |
Novartis Ag |
Immunogenic proteins and compositions
|
CN103025350A
(en)
|
2010-05-21 |
2013-04-03 |
诺华有限公司 |
Influenza virus reassortment method
|
GB201009673D0
(en)
*
|
2010-06-10 |
2010-07-21 |
Glaxosmithkline Biolog Sa |
Novel process
|
GB201009861D0
(en)
|
2010-06-11 |
2010-07-21 |
Novartis Ag |
OMV vaccines
|
EP2585106A1
(en)
|
2010-06-25 |
2013-05-01 |
Novartis AG |
Combinations of meningococcal factor h binding proteins
|
GB201017519D0
(en)
|
2010-10-15 |
2010-12-01 |
Novartis Vaccines Inst For Global Health S R L |
Vaccines
|
WO2012072769A1
(en)
|
2010-12-01 |
2012-06-07 |
Novartis Ag |
Pneumococcal rrgb epitopes and clade combinations
|
PL2667892T3
(en)
|
2011-01-26 |
2019-09-30 |
Glaxosmithkline Biologicals Sa |
Rsv immunization regimen
|
JP6191082B2
(en)
|
2011-03-02 |
2017-09-06 |
グラクソスミスクライン バイオロジカルズ ソシエテ アノニム |
Combination vaccine with lower dose of antigen and / or adjuvant
|
LT2707385T
(en)
|
2011-05-13 |
2017-12-11 |
Glaxosmithkline Biologicals Sa |
Pre-fusion rsv f antigens
|
EP2729178A1
(en)
|
2011-07-08 |
2014-05-14 |
Novartis AG |
Tyrosine ligation process
|
WO2013038375A2
(en)
|
2011-09-14 |
2013-03-21 |
Novartis Ag |
Methods for making saccharide-protein glycoconjugates
|
GB201117233D0
(en)
|
2011-10-05 |
2011-11-16 |
Stabilitech Ltd |
Stabilisation of polypeptides
|
CA2852857A1
(en)
|
2011-10-20 |
2013-04-25 |
Novartis Ag |
Adjuvanted influenza b virus vaccines for pediatric priming
|
CN104080479B
(en)
|
2011-11-07 |
2019-11-05 |
葛兰素史密丝克莱恩生物有限公司 |
Carrier molecules including spr0096 and spr2021 antigen
|
US20140335507A1
(en)
|
2011-12-12 |
2014-11-13 |
Novartis Ag |
Assays for influenza virus hemagglutinins
|
EP2793939A1
(en)
|
2011-12-23 |
2014-10-29 |
Novartis AG |
Stable compositions for immunising against staphylococcus aureus
|
ES2628301T3
(en)
|
2012-03-02 |
2017-08-02 |
Seqirus UK Limited |
Recombination of influenza virus
|
CA2866406A1
(en)
|
2012-03-08 |
2013-09-12 |
Novartis Ag |
Adjuvanted formulations of booster vaccines
|
WO2013182498A1
(en)
|
2012-06-04 |
2013-12-12 |
Novartis Ag |
Improved safety testing
|
US20150203543A1
(en)
|
2012-08-31 |
2015-07-23 |
Novartis Ag |
Stabilised proteins for immunising against staphylococcus aureus
|
ES2737024T3
(en)
|
2012-08-31 |
2020-01-09 |
Glaxosmithkline Biologicals Sa |
Proteins stabilized for immunization against Staphylococcus aureus
|
JP6324961B2
(en)
|
2012-09-06 |
2018-05-16 |
ノバルティス アーゲー |
Combination vaccine of serogroup B meningococcus and D / T / P
|
AU2013320313B2
(en)
|
2012-09-18 |
2018-07-12 |
Glaxosmithkline Biologicals Sa |
Outer membrane vesicles
|
JP2015532276A
(en)
|
2012-10-02 |
2015-11-09 |
グラクソスミスクライン バイオロジカルズ ソシエテ アノニム |
Non-linear sugar conjugate
|
GB201218195D0
(en)
|
2012-10-10 |
2012-11-21 |
Istituto Zooprofilattico Sperimentale Delle Venezie |
Composition
|
CA2886938A1
(en)
|
2012-10-12 |
2014-04-17 |
Glaxosmithkline Biologicals S.A. |
Non-cross-linked acellular pertussis antigens for use in combination vaccines
|
PL2925355T3
(en)
|
2012-11-30 |
2018-06-29 |
Glaxosmithkline Biologicals S.A. |
Pseudomonas antigens and antigen combinations
|
MX2015006927A
(en)
|
2012-12-03 |
2016-02-05 |
Novartis Ag |
Reassortant influenza a viren.
|
WO2014095771A1
(en)
|
2012-12-18 |
2014-06-26 |
Novartis Ag |
Conjugates for protecting against diphtheria and/or tetanus
|
CN111334530A
(en)
|
2013-03-13 |
2020-06-26 |
诺华股份有限公司 |
Influenza B virus reassortment
|
JP2016521282A
(en)
|
2013-05-10 |
2016-07-21 |
ノバルティス アーゲー |
Avoiding the risk of narcolepsy in influenza vaccines
|
DE202013005130U1
(en)
|
2013-06-05 |
2013-09-10 |
Novartis Ag |
Influenza virus reassortment
|
DE202013005100U1
(en)
|
2013-06-05 |
2013-08-26 |
Novartis Ag |
Influenza virus reassortment
|
BR112015030582A2
(en)
|
2013-06-06 |
2017-08-29 |
Novartis Ag |
CHIMERIC INFLUENZA HEMAGGLUTININ AND CHIMERIC NEURAMINIDASE SEGMENT, CHIMERIC HEMAGGLUTININ PROTEIN, RE-ARRANGEMENT INFLUENZA VIRUS, METHODS FOR PREPARING A RE-ARRANGEMENT INFLUENZA VIRUS AND FOR PREPARING A VACCINE AND EXPRESSION SYSTEM
|
EP2870974A1
(en)
|
2013-11-08 |
2015-05-13 |
Novartis AG |
Salmonella conjugate vaccines
|
BE1022744B1
(en)
|
2014-03-26 |
2016-08-29 |
Glaxosmithkline Biologicals Sa |
MUTANT STAPHYLOCOCCAL ANTIGENS
|
GB201406569D0
(en)
|
2014-04-11 |
2014-05-28 |
Stabilitech Ltd |
Vaccine compositions
|
JP2018524323A
(en)
|
2015-06-26 |
2018-08-30 |
セキラス ユーケー リミテッド |
Antigen matched influenza vaccine
|
US10416171B2
(en)
|
2015-07-07 |
2019-09-17 |
Seqirus UK Limited |
Influenza potency assays
|
GB2562241B
(en)
|
2017-05-08 |
2022-04-06 |
Stabilitech Biopharma Ltd |
Vaccine compositions
|
AU2020298299A1
(en)
|
2019-06-21 |
2022-02-24 |
Aarhus University |
Lipid nanodiscs solubilized through poly(acrylic acid-co-styrene) copolymers
|
GB201909680D0
(en)
|
2019-07-05 |
2019-08-21 |
Malvern Cosmeceutics Ltd |
Hypercoiling polymer derivatives
|
MX2022006005A
(en)
|
2019-11-18 |
2022-10-27 |
Seqirus Pty Ltd |
Method for producing reassortant influenza viruses.
|
US11786592B2
(en)
|
2021-05-19 |
2023-10-17 |
The University Of Hong Kong |
Compositions of cardiolipin adjuvants and methods of use thereof
|